Effect of Rosuvastatin Therapy on HDL2 Level
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.
Also called NCT02593487
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT02593487
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02593487. Randomized; single masking; primary purpose prevention. Start 2015-11 (registry gives no type); primary completion 2016-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Rosuvastatin Therapy on HDL2 Level
- Condition
- Hyperlipemia
- Condition
- Coronary Heart Disease
- Intervention (Drug)
- Rosuvastatin 10mg/d group
- Intervention (Drug)
- Rosuvastatin 20mg/d group
- Lead sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct02593487- Content hash
65867dc09fb35ea6726f429cdfd6255e5c25dc24ef5063ad0797548ee9a2879e